Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBE2109 Endometriosis-Associated Pain Phase 2b Dose-Ranging Study
2016-001736-35Phase 2Completed
- Sponsor
- ObsEva SA
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linzagolix in endometriosis (4 arms), sponsored by ObsEva SA. Primary endpoint: Primary: ≥30% reduction in mean overall pelvic pain score at week 12. Started Jul 2016; status: completed.
02
Drugs
linzagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2016-001736-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001736-35.